BL
LENZ

BFSG LLC’s LENZ Therapeutics LENZ Stock Holding History

BFSG LLC’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.61K Hold
635
– – ﹤0.01% 652
2026
Q1 		$5.81K Hold
635
– – ﹤0.01% 606
2025
Q4 		$10.2K Hold
635
– – ﹤0.01% 544
2025
Q3 		$29.6K Buy
+635
New +$23.4K ﹤0.01% 444

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

BFSG LLC's LENZ Position: Q2 2026 in Review

BFSG LLC held its LENZ Therapeutics (LENZ) position steady in Q2 2026 at 635 shares worth $3.61K. The position accounts for ﹤0.01% of the portfolio, ranked #652.

BFSG LLC first reported a position in LENZ in Q3 2025 and has held it in 4 quarters since. The position peaked at $29.6K in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • BFSG LLC held 635 shares of LENZ Therapeutics worth $3.61K as of Q2 2026.
  • BFSG LLC left its LENZ Therapeutics share count unchanged in Q2 2026.
  • LENZ Therapeutics made up ﹤0.01% of BFSG LLC's portfolio in Q2 2026, its #652 holding.
  • BFSG LLC first reported a position in LENZ Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • BFSG LLC's LENZ Therapeutics position peaked at $29.6K in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on BFSG LLC's 13F filing for Q2 2026, filed 20 Jul 2026.